Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
EGCG has shown a neuroprotective effect in cell-experimental and animal studies. The
neuroprotective mechanism of EGCG probably bases - besides the known antioxidant effect -
amongst others on the modulation of several signal transduction pathways, the influence on
the expression of genes which regulate cell survival resp. programmed cell death, as well as
the modulation of the mitochondrial function. In different Alzheimer models EGCG seems to
cause an induction of alpha-secretase and the endothelin-converting-enzyme, as well as to
prevent the aggregation of beta-amyloid to toxic oligomers through the direct binding to the
unfolded peptide.
The investigators therefore expect EGCG to have a positive influence on the course of the
Alzheimer´s Disease.